Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPRS1 | P07814 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742260 | 0.76 | EPRS1 (0.34) | EPRS1NOTUM | |
| SCHEMBL17844720 | 0.76 | F2 (0.34) | — | |
| SCHEMBL15758453 | 0.70 | PIM1 (0.35) | EPRS1NOTUM | |
| SCHEMBL17844681 | 0.70 | HDAC3 (0.35) | EPRS1NOTUM | |
| SCHEMBL17844702 | 0.69 | CACNA1H (0.33) | EPRS1NOTUM | |
| SCHEMBL17844718 | 0.69 | MCL1 (0.34) | EPRS1NOTUM | |
| SCHEMBL19742301 | 0.66 | EPRS1 (0.34) | EPRS1NOTUM | |
| SCHEMBL16345434 | 0.66 | MCL1 (0.39) | EPRS1NOTUM | |
| SCHEMBL18530490 | 0.65 | EPRS1 (0.33) | EPRS1NOTUM | |
| SCHEMBL2317964 | 0.65 | EPRS1 (0.40) | EPRS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
| WO-2016100515-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | MALT1, BCL9, BCL6 | EPRS1 2327/4885NOTUM 491/4885HRH4 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.